Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)

Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS) Clinical Trial

Official title:

Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian During Controlled Ovarian Stimulation(COH) for In Vitro Fertilisation(IVF)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01109888
• Other study ID #: 12101967
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• First received: April 22, 2010
• Last updated: March 29, 2016

Study information

• Verified date: April 2010
• Source: Wolfson Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Coasting is one of the means to reduce the risk of OHSS for patients at risk for severe OHSS. During coasting gonadotrophin administration is withheld until serum E2 levels drop to a range considered safe. Prolonged coasting reduces the chance for implantation and pregnancy. The aim of the study is to explore whether an increased dose of GnRH Antagonist will shorten the coasting period without an adverse effect on cycle outcome.

Description:

30 patients undergoing IVF using a GnRH antagonist protocol that present with a high response to gonadotrophin stimulation, will be randomized into one of two groups: group A - withdrawal of gonadotrophin support and continue a daily dose of 0.25 mg of the GnRH antagonist. group B - withdrawal of gonadotrophin support and continue a double daily dose of 0.5 mg of the GnRH antagonist.

The main outcome measures will be the duration of coasting (days)and the rate of serum E2 drop (%).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Gender: Female
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:30 women undergoing IVF cycle with GnRH Antagonist protocol under 35 years old.

E2 higher than 3000 pg/ml. -

Exclusion Criteria: 3 or more failed fresh IVF cycles.

Study Design

N/A

Related Conditions & MeSH terms

• Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)
• Ovarian Hyperstimulation Syndrome

Intervention

Drug:
• Cetrotide

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Wolfson Medical Center